Skip to main content

Table 2 Distribution of study covariates and hospital outcomes of patients with and without T2DM hospitalized with infective endocarditis in Spain from 2001 to 2015, before and after propensity score matching

From: Infective endocarditis according to type 2 diabetes mellitus status: an observational study in Spain, 2001–2015

 

Before matching

After matching

T2DM

Non T2DM

p value

T2DM

Non T2DM

p value

Time period, n (%)

 2001–2003

345 (10.0)

2019 (15.3)

< 0.001

345 (10.0)

371 (10.8)

0.277

 2004–2006

486 (14.1)

2128 (16.1)

486 (14.1)

456 (13.3)

 2007–2009

603 (17.6)

2304 (17.5)

603 (17.6)

576 (16.8)

 2010–2012

962 (28.0)

3165 (24.0)

962 (28.0)

928 (27.0)

 2013–2015

1040 (30.3)

3574 (27.1)

1040 (30.3)

1105 (32.2)

 Total

3436 (100)

13,190 (100)

3436 (100)

3436 (100)

Sex, n (%)

 Male

2196 (63.9)

8865 (67.2)

< 0.001

2196 (63.9)

2175 (63.3)

0.599

 Female

1240 (36.1)

4325 (32.8)

1240 (36.1)

1261 (36.7)

Age, mean (SD)

70.8 (10.2)

67.9 (12.4)

< 0.001

70.8 (10.2)

70.3 (11.8)

0.154

Age groups, n (%)

 40–66 years old

1030 (30.0)

5437 (41.2)

< 0.001

1030 (30.0)

1067 (31.1)

0.001

 67–75 years old

1153 (33.6)

3547 (26.9)

1153 (33.6)

1014 (29.5)

 ≥ 76 years old

1253 (36.5)

4206 (31.9)

1253 (36.5)

1355 (39.4)

CCI, mean (SD)

1.1 (0.8)

0.9 (0.8)

< 0.001

1.1 (0.8)

1.1 (0.8)

0.673

Prosthetic valve carriers, n (%)

333 (9.7)

1220 (9.3)

0.428

333 (9.7)

306 (8.9)

0.262

Previous mitral valve disease, n (%)

912 (26.5)

3971 (30.1)

< 0.001

912 (26.5)

908 (26.4)

0.913

Previous aortic valve disease, n (%)

869 (25.3)

3880 (29.4)

< 0.001

869 (25.3)

846 (24.6)

0.521

Congestive heart failure, n (%)

972 (28.3)

3666 (27.8)

0.565

972 (28.3)

935 (27.2)

0.319

Septic arterial embolism, n (%)

39 (1.1)

164 (1.2)

0.607

39 (1.1)

46 (1.3)

0.445

Dementia, n (%)

61 (1.8)

153 (1.2)

0.004

61 (1.8)

56 (1.6)

0.641

Acute renal disease, n (%)

617 (18.0)

2432 (18.4)

0.516

617 (18.0)

598 (17.4)

0.548

Chronic renal disease, n (%)

592 (17.2)

1329 (10.1)

< 0.001

592 (17.2)

536 (15.6)

0.068

Ischemic heart disease, n (%)

627 (18.3)

1467 (11.1)

< 0.001

627 (18.3)

611 (17.8)

0.616

COPD, n (%)

602 (17.5)

2167 (16.4)

0.126

602 (17.5)

643 (18.7)

0.199

Atrial fibrillation, n (%)

863 (25.1)

2916 (22.1)

< 0.001

863 (25.1)

867 (25.2)

0.911

Shock, n (%)

239 (7.0)

1099 (8.3)

0.008

239 (7.0)

221 (6.4)

0.385

Periannular complications/atrioventricular block, n (%)

129 (3.8)

600 (4.6)

0.043

129 (3.8)

165 (4.8)

0.032

Heart valve surgery, n (%)

479 (13.9)

2630 (19.9)

< 0.001

479 (13.9)

595 (17.3)

< 0.001

Dialysis, n (%)

248 (7.2)

761 (5.8)

< 0.001

248 (7.2)

203 (5.9)

0.028

Pacemaker implantation, n (%)

89 (2.6)

356 (2.7)

0.725

89 (2.6)

86 (2.5)

0.818

Mechanical ventilation, n (%)

410 (11.9)

1774 (13.5)

0.019

410 (11.9)

412 (12.0)

0.941

Coagulase-negative staphylococci, n (%)

441 (12.8)

1463 (11.1)

0.004

441 (12.8)

399 (11.6)

0.122

Staphylococcus aureus, n (%)

504 (14.7)

1685 (12.8)

0.003

504 (14.7)

452 (13.2)

0.070

Streptococci, n (%)

649 (18.9)

2897 (22.0)

< 0.001

649 (18.9)

749 (21.8)

0.003

Enterococci, n (%)

557 (16.2)

1887 (14.3)

0.005

557 (16.2)

488 (14.2)

0.020

Streptococcus pneumoniae, n (%)

15 (0.4)

58 (0.4)

0.980

15 (0.4)

13 (0.4)

0.705

Anaerobes, n (%)

21 (0.6)

71 (0.5)

0.608

21 (0.6)

19 (0.6)

0.751

Gram-negative bacilli, n (%)

264 (7.7)

1012 (7.7)

0.983

264 (7.7)

260 (7.6)

0.856

Candidiasis/aspergillosis, n (%)

3 (0.1)

32 (0.2)

0.077

3 (0.1)

11 (0.3)

0.032

Readmissions, n (%)

687 (20.0)

2091 (15.9)

< 0.001

687 (20.0)

632 (18.4)

0.092

Length of hospital stay, mean (SD)

27.17 (20.4)

27.51 (22.1)

0.405

27.17 (20.4)

27.43 (22.1)

0.616

In-hospital mortality, n (%)

714 (20.8)

2562 (19.4)

0.075

714 (20.8)

682 (19.9)

0.337

Cost, mean (SD)

13,230.4 (10,000.7)

14,452.0 (12,845.6)

< 0.001

13,230.4 (10,000.7)

14,045.3 (12,713.2)

0.003

  1. T2DM type 2 diabetes mellitus, SD standard deviation, CCI Charlson Comorbidity Index, COPD chronic obstructive pulmonary disease